A Psychedelic and Cannabis Research Revolution On the Horizon?

About this episode

This episode discusses the shift in federal drug policy regarding psychedelics and its implications for the cannabis market.

This episode of Blunt Business explores a significant shift in federal drug policy following a new executive order aimed at accelerating research into psychedelics like LSD, psilocybin, and ibogaine for treating mental health disorders. The newly signed executive order to direct the FDA to fast-track these compounds through new "National Priority" vouchers. Beyond psychedelics, the host discusses the impact of GLP-1 weight-loss drugs (like Ozempic) on the cannabis market, noting that dispensaries are seeing a shift in consumer preference toward lower-dose products to mitigate "the munchies." Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy

People in this episode

Host: unknown

Topics covered

• federal drug policy
• psychedelics research
• mental health treatment
• cannabis market
• consumer preferences
• weight-loss drugs

Keywords

• psychedelics
• cannabis
• FDA
• mental health
• drug policy
• consumer preferences
• weight-loss

Mentioned in this episode

Organizations: FDA

Products: LSD, psilocybin, ibogaine, GLP-1 weight-loss drugs, Ozempic

More episodes of Blunt Business

• Kazmira Therapeutics and the Future of CBD Medicine · June 10, 2026 · 28 min
• The Hemp Lifeline: States Open Cannabis Gateways as Federal Lawsuit Targets MSOs · June 3, 2026 · 23 min
• Federal Rescheduling and the BUILD Act: Capitol Hill’s Shift on Cannabis Reform · May 27, 2026 · 25 min
• Georgia Expands Medical Access and D.C. Beats Cannabis Lawsuit · May 20, 2026 · 19 min
• $15 Billion Refund? Navigating Retroactive 280E Relief · May 13, 2026 · 25 min
• Can Las Vegas Cash In on the Cannabis Reclassification? · May 6, 2026 · 31 min